Oncolytics Biotech Inc T.ONC

A layman's thoughts on Roche and Adaptive Phase 3.

[pelaboost]

I do not recall if we knew the PDAC Phase 3 was to be an Adaptive Phase 3. We have known for some time that the CPI was to be Tecentriq. Being an Adaptive Trial allows considerable flexibility (to allow for Cohort 5 of GOBLET and other changes), and the possibity of being a confirmatory trial.

We do not yet know how ONC/ONCY is going to fund this trial. I cannot see Roche stepping too far away from this, but until I have something material, I only know that Roche is supplying the CPI.

I would like to think that PanCAN is still involved in some capacity.

It does now seem  a safe bet that there will be a Phase 3 pancreatic cancer trial.

[askretka]

I think idea for adaptive P3 came from PanCan.  They had ok from FDA to run such a program.  Because Pancreatic Cancer is so brutal and spreads so fast I think they ok'd the idea of an adaptive type program with an ongoing running control arm because of the huge unmet need in Pancreatic cancer that is well on track to become the number two in cancer deaths worldwide. I still think

[Noteable]

The Phase 2 trials Reo-17 and GOBLET-1 were both adaptive clinical trials and a Phase 3 confirmation study is simply a follow-on adaptive designed study based on the previous Phase 2, as I have posted here beforehand.